The directors/management could be privy to information that a...

The directors/management could be privy to information that a massive buyout is in discussion and still participate. That is why it is subject to shareholder approval. We decide if they are allowed to participate.
What I would have liked to see on the poster at the stockholm conference is the trial participants split into cohort 1 and 2. Based on the length of time on the trial it can be determined, although I believe 1 participant transferred from cohort 1 to cohort 2 and 1 participant started late in cohort 1. Looking at the individual participants to their matched expected rate of decline, most of cohort 2 are outperforming nearly all matched data. A massive confidence boost for me on the effect the high dose is having. Now let's get this trial underway and make a real difference to people with ALS/MND.